Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

Podobne zapisy

• Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
  od: Blum, William, i wsp.
  Wydane: (2010)
• Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
  od: Phelps, Mitch A., i wsp.
  Wydane: (2009)
• Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule
  od: Phelps, Mitch A,, i wsp.
  Wydane: (2008)
• Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity in Relapsed and Refractory Non-Hodgkin’s Lymphoma
  od: Jones, Jeffrey A., i wsp.
  Wydane: (2013)
• Reduced Occurrence of Tumor Flare with Flavopiridol Followed by Combined Flavopiridol and Lenalidomidein Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
  od: Maddocks, Kami, i wsp.
  Wydane: (2015)